Chimeric hexon HVRs protein reflects partial function of adenovirus

Biochemical and Biophysical Research Communications

Volumn 421, Issue 2, 2012, Pages 170-176

  Yu, Bin ^a   Wang, Chu ^a   Dong, Jianing ^a   Zhang, Min ^b   Zhang, Haihong ^a   Wu, Jiaxin ^a   Wu, Yuqing ^b   Kong, Wei ^a   Yu, Xianghui ^a  

^a JILIN UNIVERSITY   (China)

^b Jilin University   (China)

Author keywords

Adenovirus; FX; Hexon; HVRs; NAbs

Indexed keywords

BLOOD CLOTTING FACTOR 10; CHIMERIC PROTEIN; NEUTRALIZING ANTIBODY;

ADENOVIRUS; ADENOVIRUS 5; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SEROTYPE;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; CAPSID PROTEINS; EPITOPES; FACTOR X; GENE THERAPY; HEK293 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; PLASMIDS; PROTEIN CONFORMATION; RECOMBINANT FUSION PROTEINS; VIRAL VACCINES;

ADENOVIRIDAE;

EID: 84860491641     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.03.125     Document Type: Article

References (17)

1. Mast T.C., Kierstead L., Gupta S.B., Nikas A.A., Kallas E.G., Novitsky V., Mbewe B., Pitisuttithum P., Schechter M., Vardas E., Wolfe N.D., Aste-Amezaga M., Casimiro D.R., Coplan P., Straus W.L., Shiver J.W. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010, 28:950-957.
2. Barouch D.H., Kik S.V., Weverling G.J., Dilan R., King S.L., Maxfield L.F., Clark S., Ng'ang'a D., Brandariz K.L., Abbink P., Sinangil F., de Bruyn G., Gray G.E., Roux S., Bekker L.-G., Dilraj A., Kibuuka H., Robb M.L., Michael N.L., Anzala O., Amornkul P.N., Gilmour J., Hural J., Buchbinder S.P., Seaman M.S., Dolin R., Baden L.R., Carville A., Mansfield K.G., Pau M.G., Goudsmit J. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 2011, 29:5203-5209.
3. Roberts D.M., Nanda A., Havenga M.J., Abbink P., Lynch D.M., Ewald B.A., Liu J., Thorner A.R., Swanson P.E., Gorgone D.A., Lifton M.A., Lemckert A.A., Holterman L., Chen B., Dilraj A., Carville A., Mansfield K.G., Goudsmit J., Barouch D.H. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006, 441:239-243.
4. Bradley R.R., Maxfield L.F., Lynch D.M., Iampietro M.J., Borducchi E.N., Barouch D.H. Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions. J. Virol. 2012, 86:1267-1272.
5. Seregin S.S., Amalfitano A. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors. Expert Opin. Biol. Ther. 2009, 9:1521-1531.
6. Waddington S.N., McVey J.H., Bhella D., Parker A.L., Barker K., Atoda H., Pink R., Buckley S.M., Greig J.A., Denby L., Custers J., Morita T., Francischetti I.M., Monteiro R.Q., Barouch D.H., van Rooijen N., Napoli C., Havenga M.J., Nicklin S.A., Baker A.H. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008, 132:397-409.
7. Alba R., Bradshaw A.C., Parker A.L., Bhella D., Waddington S.N., Nicklin S.A., van Rooijen N., Custers J., Goudsmit J., Barouch D.H., McVey J.H., Baker A.H. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 2009, 114:965-971.
8. Ng P., Parks R.J., Cummings D.T., Evelegh C.M., Graham F.L. An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method. Hum. Gene Ther. 2000, 11:693-699.
9. Ng P., Parks R.J., Cummings D.T., Evelegh C.M., Sankar U., Graham F.L. A high-efficiency Cre/loxP-based system for construction of adenoviral vectors. Hum. Gene Ther. 1999, 10:2667-2672.
10. Sprangers M.C., Lakhai W., Koudstaal W., Verhoeven M., Koel B.F., Vogels R., Goudsmit J., Havenga M.J., Kostense S. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J. Clin. Microbiol. 2003, 41:5046-5052.
11. Wittig I., Beckhaus T., Wumaier Z., Karas M., Schagger H. Mass estimation of native proteins by blue native electrophoresis: principles and practical hints. Mol. Cell. Proteomics 2010, 9:2149-2161.
12. Roberts M.M., White J.L., Grutter M.G., Burnett R.M. Three-dimensional structure of the adenovirus major coat protein hexon. Science 1986, 232:1148-1151.
13. Wen Z.Z., Wang Y.H., Yang B., Xie M.Q., Chou K.C. Roles of L5-7 loop in the structure and chaperone function of SsHSP14.1. Protein Pept. Lett. 2011, 18:275-281.
14. Toogood C.I., Crompton J., Hay R.T. Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J. Gen. Virol. 1992, 73(Pt 6):1429-1435.
15. Takeuchi S., Itoh N., Uchio E., Aoki K., Ohno S. Serotyping of adenoviruses on conjunctival scrapings by PCR and sequence analysis. J. Clin. Microbiol. 1999, 37:1839-1845.
16. Pichla-Gollon S.L., Drinker M., Zhou X., Xue F., Rux J.J., Gao G.P., Wilson J.M., Ertl H.C., Burnett R.M., Bergelson J.M. Structure-based identification of a major neutralizing site in an adenovirus hexon. J. Virol. 2007, 81:1680-1689.
17. Kalyuzhniy O., Di Paolo N.C., Silvestry M., Hofherr S.E., Barry M.A., Stewart P.L., Shayakhmetov D.M. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl. Acad. Sci. USA 2008, 105:5483-5488.